Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD)

G. Valen, M. Runsiö, A. Öwall, J. Kaszaki, S. Nagy, M. Rosenqvist, L. Bergfeldt, J. Vaage

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Histamine has inotropic, chronotropic, arrhythmogenic, and vasoactive effects, and is released from the heart in ischaemia-reperfusion injury. The effect of ventricular fibrillation (VF) and defibrillation (DEF) on histamine release was investigated in 9 anaesthetized patients undergoing transvenous implantation of ICD. Concomitant arterial and coronary sinus (CS) blood samples were drawn before induction of VF (duration 20 seconds), immediately after, and 2 and 5min after DEF (18-24 Joules). Basal arterial histamine was 2.5±6nmol/1, and did not increase after VF. The histamine level in CS was 1.1±0.2nmol/1 before VF (p <0.008 compared to arterial), and increased to 2.5 ± 0.6 nmol/1 immediately after (p <0.045 compared to basal), to 3 ± 1.1 nmol/1 2 min after (p <0.45), and to 2.4 ± 0.8 nmol/1 5min after VF. In the basal state there was an uptake of histamine across the coronary circulation. After VF/DEF the level of histamine increased in coronary venous blood, suggesting cardiac release of histamine.

Original languageEnglish
Pages (from-to)499-503
Number of pages5
JournalInflammation Research
Volume44
Issue number11
DOIs
Publication statusPublished - Nov 1995

Fingerprint

Implantable cardioverter defibrillators
Implantable Defibrillators
Histamine Release
Ventricular Fibrillation
Histamine
Coronary Sinus
Blood
Coronary Circulation
Reperfusion Injury

Keywords

  • Histamine
  • Hypoperfusion
  • Implantable defibrillators
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)
  • Immunology
  • Cell Biology

Cite this

Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD). / Valen, G.; Runsiö, M.; Öwall, A.; Kaszaki, J.; Nagy, S.; Rosenqvist, M.; Bergfeldt, L.; Vaage, J.

In: Inflammation Research, Vol. 44, No. 11, 11.1995, p. 499-503.

Research output: Contribution to journalArticle

Valen, G. ; Runsiö, M. ; Öwall, A. ; Kaszaki, J. ; Nagy, S. ; Rosenqvist, M. ; Bergfeldt, L. ; Vaage, J. / Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD). In: Inflammation Research. 1995 ; Vol. 44, No. 11. pp. 499-503.
@article{95c73e9408d54148ba2af58c33eb6e4b,
title = "Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD)",
abstract = "Histamine has inotropic, chronotropic, arrhythmogenic, and vasoactive effects, and is released from the heart in ischaemia-reperfusion injury. The effect of ventricular fibrillation (VF) and defibrillation (DEF) on histamine release was investigated in 9 anaesthetized patients undergoing transvenous implantation of ICD. Concomitant arterial and coronary sinus (CS) blood samples were drawn before induction of VF (duration 20 seconds), immediately after, and 2 and 5min after DEF (18-24 Joules). Basal arterial histamine was 2.5±6nmol/1, and did not increase after VF. The histamine level in CS was 1.1±0.2nmol/1 before VF (p <0.008 compared to arterial), and increased to 2.5 ± 0.6 nmol/1 immediately after (p <0.045 compared to basal), to 3 ± 1.1 nmol/1 2 min after (p <0.45), and to 2.4 ± 0.8 nmol/1 5min after VF. In the basal state there was an uptake of histamine across the coronary circulation. After VF/DEF the level of histamine increased in coronary venous blood, suggesting cardiac release of histamine.",
keywords = "Histamine, Hypoperfusion, Implantable defibrillators, Ventricular fibrillation",
author = "G. Valen and M. Runsi{\"o} and A. {\"O}wall and J. Kaszaki and S. Nagy and M. Rosenqvist and L. Bergfeldt and J. Vaage",
year = "1995",
month = "11",
doi = "10.1007/BF01837917",
language = "English",
volume = "44",
pages = "499--503",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "11",

}

TY - JOUR

T1 - Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD)

AU - Valen, G.

AU - Runsiö, M.

AU - Öwall, A.

AU - Kaszaki, J.

AU - Nagy, S.

AU - Rosenqvist, M.

AU - Bergfeldt, L.

AU - Vaage, J.

PY - 1995/11

Y1 - 1995/11

N2 - Histamine has inotropic, chronotropic, arrhythmogenic, and vasoactive effects, and is released from the heart in ischaemia-reperfusion injury. The effect of ventricular fibrillation (VF) and defibrillation (DEF) on histamine release was investigated in 9 anaesthetized patients undergoing transvenous implantation of ICD. Concomitant arterial and coronary sinus (CS) blood samples were drawn before induction of VF (duration 20 seconds), immediately after, and 2 and 5min after DEF (18-24 Joules). Basal arterial histamine was 2.5±6nmol/1, and did not increase after VF. The histamine level in CS was 1.1±0.2nmol/1 before VF (p <0.008 compared to arterial), and increased to 2.5 ± 0.6 nmol/1 immediately after (p <0.045 compared to basal), to 3 ± 1.1 nmol/1 2 min after (p <0.45), and to 2.4 ± 0.8 nmol/1 5min after VF. In the basal state there was an uptake of histamine across the coronary circulation. After VF/DEF the level of histamine increased in coronary venous blood, suggesting cardiac release of histamine.

AB - Histamine has inotropic, chronotropic, arrhythmogenic, and vasoactive effects, and is released from the heart in ischaemia-reperfusion injury. The effect of ventricular fibrillation (VF) and defibrillation (DEF) on histamine release was investigated in 9 anaesthetized patients undergoing transvenous implantation of ICD. Concomitant arterial and coronary sinus (CS) blood samples were drawn before induction of VF (duration 20 seconds), immediately after, and 2 and 5min after DEF (18-24 Joules). Basal arterial histamine was 2.5±6nmol/1, and did not increase after VF. The histamine level in CS was 1.1±0.2nmol/1 before VF (p <0.008 compared to arterial), and increased to 2.5 ± 0.6 nmol/1 immediately after (p <0.045 compared to basal), to 3 ± 1.1 nmol/1 2 min after (p <0.45), and to 2.4 ± 0.8 nmol/1 5min after VF. In the basal state there was an uptake of histamine across the coronary circulation. After VF/DEF the level of histamine increased in coronary venous blood, suggesting cardiac release of histamine.

KW - Histamine

KW - Hypoperfusion

KW - Implantable defibrillators

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0028806837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028806837&partnerID=8YFLogxK

U2 - 10.1007/BF01837917

DO - 10.1007/BF01837917

M3 - Article

C2 - 8597885

AN - SCOPUS:0028806837

VL - 44

SP - 499

EP - 503

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 11

ER -